News
Second UK Covid-19 vaccine manufacturing site gets MHRA approval
The second of two GMP manufacturing sites for the UK’s specialist vaccines manufacturing equipment has been approved by the Medicines & Healthcare products Regulatory Agency (MHRA).
Announced by the Vaccines Manufacturing and Innovation Centre (VMIC), the new site means there...
News
Zydus Cadila Covid vaccine likely to be ready by March 2021
Phase-2 trials of Zydus Cadila's indigenous vaccine ZyCoV-D is moving in the right direction and the data will be available by the end of November and the vaccine is likely to be available by March 2021, said Pankaj R...
Drug Research
iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming System
iBio, Inc., a biotech innovator and biologics contract manufacturing organization, announced that it has entered into a Master Services Agreement (“MSA”) with Boston-based Safi Biosolutions, Inc. (“Safi”) to evaluate iBio’s FastPharming® System for the expression of key proteins to...
Clinical Trials
Kodiak begins three phase 3 studies of anti-VEGF antibody biopolymer conjugate, KSI-301 to treat DME and macular edema due to retinal vein occlusion
Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced that the first patients have been treated in the randomized, double-masked GLEAM, GLIMMER and BEACON studies, three pivotal...
News
Blue Dart strengthens temperature controlled logistics solution to fight against COVID-19
Blue Dart, India’s leading express logistics service provider and part of the Deutsche Post DHL Group (DPDHL) with its commitment to help improve the supply chain and ensure timely medical provisions is ramping up its infrastructure with its pre-existing...
News
Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis
Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for SB11, a proposed biosimilar referencing Lucentis® (ranibizumab). Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for...
News
Gilead takes over distribution of Covid-19 antiviral drug from federal government
The maker of the first antiviral drug to get authorization from regulators for Covid-19 anticipates meeting real-time demand for it around the world this month and is already meeting demand in the U.S.
Foster City, California-based Gilead Sciences said Thursday...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
